Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer - An Open Label, Non-comparative, Randomized, Multicenter Phase II Trial
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2018
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Biliary tract disorders
- Focus Therapeutic Use
- Acronyms NIFE
- 22 Mar 2018 Status changed from not yet recruiting to recruiting.
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
- 08 Aug 2017 Planned initiation date changed from 1 May 2017 to 1 Nov 2017.